BR112016020643A2 - anticorpos específicos para receptor de fator de crescimento semelhante à insulina tipo 1 e uso dos mesmos - Google Patents
anticorpos específicos para receptor de fator de crescimento semelhante à insulina tipo 1 e uso dos mesmosInfo
- Publication number
- BR112016020643A2 BR112016020643A2 BR112016020643A BR112016020643A BR112016020643A2 BR 112016020643 A2 BR112016020643 A2 BR 112016020643A2 BR 112016020643 A BR112016020643 A BR 112016020643A BR 112016020643 A BR112016020643 A BR 112016020643A BR 112016020643 A2 BR112016020643 A2 BR 112016020643A2
- Authority
- BR
- Brazil
- Prior art keywords
- bhe
- insulin
- growth factor
- factor receptor
- type
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
Abstract
a barreira hematoencefálica (bhe) impede o transporte de moléculas maiores do que 500 daltons do sangue para o cérebro. a transcitose mediada por receptor (rmt) facilita o transporte através da bhe de moléculas específicas que ligam os receptores em células endoteliais cerebrais que formam a bhe. um anticorpo de ligação a receptor de fator de crescimento semelhante à insulina tipo 1 (igf 1r) ou fragmento do mesmo é identificado que transmigra a bhe por rmt. o anticorpo ou fragmento é usado para entregar uma molécula de carga através da bhe, em que a molécula de carga pode ser um agente terapêutico ou detectável. o anticorpo é um vhh de camelídeo preparado imunizando-se uma lhama com um polipeptídeo de igf 1r com 933 aminoácidos. formas humanizadas do vhh de camelídeo são também geradas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461948831P | 2014-03-06 | 2014-03-06 | |
US61/948,831 | 2014-03-06 | ||
PCT/CA2014/000862 WO2015131258A1 (en) | 2014-03-06 | 2014-12-04 | Insulin-like growth factor 1 receptor -specific antibodies and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112016020643A2 true BR112016020643A2 (pt) | 2018-01-23 |
BR112016020643B1 BR112016020643B1 (pt) | 2023-05-02 |
Family
ID=54054288
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016020643-6A BR112016020643B1 (pt) | 2014-03-06 | 2014-12-04 | Anticorpos específicos para receptor de fator de crescimento semelhante à insulina tipo 1 e uso dos mesmos |
Country Status (18)
Country | Link |
---|---|
US (1) | US10100117B2 (pt) |
EP (1) | EP3114140B1 (pt) |
JP (1) | JP6541236B2 (pt) |
KR (1) | KR102355309B1 (pt) |
CN (1) | CN106536555B (pt) |
AU (1) | AU2014385801B2 (pt) |
BR (1) | BR112016020643B1 (pt) |
CA (1) | CA2941654C (pt) |
CL (1) | CL2016002245A1 (pt) |
DK (1) | DK3114140T3 (pt) |
EA (1) | EA035517B1 (pt) |
IL (1) | IL247607B (pt) |
MX (1) | MX2016011557A (pt) |
NZ (1) | NZ724869A (pt) |
PE (1) | PE20161245A1 (pt) |
UA (1) | UA120047C2 (pt) |
WO (1) | WO2015131258A1 (pt) |
ZA (1) | ZA201606212B (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6541236B2 (ja) | 2014-03-06 | 2019-07-10 | ナショナル リサーチ カウンシル オブ カナダ | インスリン様成長因子1受容体特異的抗体及びそれらの使用 |
KR102355310B1 (ko) | 2014-03-06 | 2022-01-24 | 내셔날 리서치 카운실 오브 캐나다 | 인슐린-유사 성장 인자 1 수용체-특이적 항체 및 그의 용도 |
UA120048C2 (uk) | 2014-03-06 | 2019-09-25 | Нешнл Рісеч Каунсіл Оф Канада | Антигензв'язуючий фрагмент антитіла, який специфічно зв'язується з рецептором інсуліноподібного фактора росту 1 (igf1r) |
AU2017293450A1 (en) * | 2016-07-06 | 2019-02-14 | National Research Council Of Canada | Humanized antibodies transmigrating the blood-brain barrier and uses thereof |
CN110382522A (zh) * | 2017-01-30 | 2019-10-25 | 加拿大国家研究委员会 | 血脑屏障穿过化合物及其用途 |
KR20200033880A (ko) | 2017-08-02 | 2020-03-30 | 스트레스마크 바이오사이언시즈 인코퍼레이티드 | 항체 결합 활성 알파 시누클레인 |
CN116731173A (zh) * | 2017-12-14 | 2023-09-12 | Abl生物公司 | 抗a-syn/igf1r的双特异性抗体及其用途 |
CA3098162A1 (en) * | 2018-04-24 | 2019-10-31 | National Research Council Of Canada | Blood-brain barrier transmigrating therapeutic compounds and uses thereof |
CN113474369A (zh) * | 2019-01-09 | 2021-10-01 | 维克塔-霍洛斯公司 | 转铁蛋白受体结合分子、其偶联物和它们的用途 |
PE20220516A1 (es) * | 2019-06-14 | 2022-04-07 | Abl Bio Inc | ANTICUERPO BIESPECIFICO CONTRA (alfa)-SYN/IGF1R Y USO DEL MISMO |
JP2023508596A (ja) | 2020-01-02 | 2023-03-02 | エフ. ホフマン-ラ ロシュ アーゲー | 脳内の治療用抗体の量を決定するための方法 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
ES2202310T3 (es) | 1991-12-13 | 2004-04-01 | Xoma Corporation | Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos. |
EP0711303B2 (en) | 1993-07-30 | 2009-06-10 | Affymax, Inc. | Biotinylation of proteins |
WO2001007084A1 (en) * | 1999-07-23 | 2001-02-01 | Regents Of The University Of California | Anti-growth factor receptor avidin fusion proteins as universal vectors for drug delivery |
US20030190598A1 (en) * | 2000-05-26 | 2003-10-09 | Jasmid Tanha | Single-domain antigen-binding antibody fragments derived from llama antibodies |
CA2441903C (en) | 2000-05-26 | 2012-07-31 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
BR0214621A (pt) | 2001-11-30 | 2004-10-13 | Ca Nat Research Council | Moléculas de automontagem |
US7388079B2 (en) * | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
US20050142141A1 (en) * | 2002-11-27 | 2005-06-30 | Pardridge William M. | Delivery of enzymes to the brain |
EP1452601A1 (en) | 2003-02-28 | 2004-09-01 | Roche Diagnostics GmbH | Enhanced expression of fusion polypeptides with a biotinylation tag |
WO2007000328A1 (en) * | 2005-06-27 | 2007-01-04 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof |
EP1943341A4 (en) | 2005-09-27 | 2010-07-07 | Ca Nat Research Council | HEMATOENCEPHALIC BARRIER EPITOPES AND USES THEREOF |
US20090252681A1 (en) * | 2005-10-11 | 2009-10-08 | Ablynx N.V. | Nanobodies and Polypeptides Against EGFR and IGF-IR |
AU2006301426A1 (en) * | 2005-10-11 | 2007-04-19 | Ablynx N.V. | NanobodiesTM and polypeptides against EGFR and IGF-IR |
US7981417B2 (en) | 2006-06-07 | 2011-07-19 | Wisconsin Alumni Research Foundation | Blood-brain barrier targeting anti-bodies |
EP2029621A2 (en) | 2006-06-07 | 2009-03-04 | Wisconsin Alumni Research Foundation | Blood-brain barrier targeting antibodies |
CA2661042C (en) | 2006-08-18 | 2012-12-11 | Armagen Technologies, Inc. | Agents for blood-brain barrier delivery |
KR20100052545A (ko) | 2007-08-28 | 2010-05-19 | 바이오겐 아이덱 엠에이 인코포레이티드 | Igf―1r의 다중 에피토프에 결합하는 조성물 |
US8444976B2 (en) * | 2008-07-02 | 2013-05-21 | Argen-X B.V. | Antigen binding polypeptides |
WO2011044542A1 (en) | 2009-10-09 | 2011-04-14 | Armagen Technologies, Inc. | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
US8444982B2 (en) * | 2009-12-04 | 2013-05-21 | The University Of Hong Kong | Anti-IGF-IR antibodies and uses thereof |
CA2796215C (en) | 2010-04-14 | 2021-05-18 | National Research Council Of Canada | Compositions and methods for brain delivery of analgesic peptides |
UA107596C2 (uk) * | 2010-05-27 | 2015-01-26 | Виділений поліпептид, який зв'язується з рецептором інсуліноподібного фактора росту 1 | |
KR102099462B1 (ko) | 2010-11-30 | 2020-04-10 | 제넨테크, 인크. | 저친화도 혈액-뇌 장벽 수용체 항체 및 그의 용도 |
PL2802606T3 (pl) * | 2012-01-10 | 2018-09-28 | Biogen Ma Inc. | Udoskonalenie transportu cząsteczek terapeutycznych przez barierę krew-mózg |
UA120048C2 (uk) | 2014-03-06 | 2019-09-25 | Нешнл Рісеч Каунсіл Оф Канада | Антигензв'язуючий фрагмент антитіла, який специфічно зв'язується з рецептором інсуліноподібного фактора росту 1 (igf1r) |
JP6541236B2 (ja) | 2014-03-06 | 2019-07-10 | ナショナル リサーチ カウンシル オブ カナダ | インスリン様成長因子1受容体特異的抗体及びそれらの使用 |
KR102355310B1 (ko) | 2014-03-06 | 2022-01-24 | 내셔날 리서치 카운실 오브 캐나다 | 인슐린-유사 성장 인자 1 수용체-특이적 항체 및 그의 용도 |
-
2014
- 2014-12-04 JP JP2016555678A patent/JP6541236B2/ja active Active
- 2014-12-04 CN CN201480078382.8A patent/CN106536555B/zh active Active
- 2014-12-04 MX MX2016011557A patent/MX2016011557A/es active IP Right Grant
- 2014-12-04 KR KR1020167027256A patent/KR102355309B1/ko active IP Right Grant
- 2014-12-04 EP EP14884539.9A patent/EP3114140B1/en active Active
- 2014-12-04 WO PCT/CA2014/000862 patent/WO2015131258A1/en active Application Filing
- 2014-12-04 US US15/123,735 patent/US10100117B2/en active Active
- 2014-12-04 AU AU2014385801A patent/AU2014385801B2/en active Active
- 2014-12-04 CA CA2941654A patent/CA2941654C/en active Active
- 2014-12-04 PE PE2016001574A patent/PE20161245A1/es unknown
- 2014-12-04 DK DK14884539.9T patent/DK3114140T3/da active
- 2014-12-04 UA UAA201610008A patent/UA120047C2/uk unknown
- 2014-12-04 BR BR112016020643-6A patent/BR112016020643B1/pt active IP Right Grant
- 2014-12-04 NZ NZ724869A patent/NZ724869A/en unknown
- 2014-12-04 EA EA201691782A patent/EA035517B1/ru unknown
-
2016
- 2016-09-04 IL IL247607A patent/IL247607B/en active IP Right Grant
- 2016-09-06 CL CL2016002245A patent/CL2016002245A1/es unknown
- 2016-09-07 ZA ZA2016/06212A patent/ZA201606212B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3114140B1 (en) | 2019-02-27 |
KR20160130436A (ko) | 2016-11-11 |
IL247607B (en) | 2020-03-31 |
DK3114140T3 (da) | 2019-06-03 |
PE20161245A1 (es) | 2016-11-25 |
ZA201606212B (en) | 2019-01-30 |
BR112016020643B1 (pt) | 2023-05-02 |
EA201691782A1 (ru) | 2017-01-30 |
CL2016002245A1 (es) | 2017-04-07 |
UA120047C2 (uk) | 2019-09-25 |
EP3114140A1 (en) | 2017-01-11 |
EA035517B1 (ru) | 2020-06-29 |
CN106536555B (zh) | 2019-10-18 |
CA2941654A1 (en) | 2015-09-11 |
NZ724869A (en) | 2022-07-01 |
AU2014385801B2 (en) | 2020-11-12 |
IL247607A0 (en) | 2016-11-30 |
CA2941654C (en) | 2023-08-08 |
US20170015748A1 (en) | 2017-01-19 |
AU2014385801A1 (en) | 2016-10-20 |
KR102355309B1 (ko) | 2022-01-24 |
WO2015131258A1 (en) | 2015-09-11 |
JP2017513461A (ja) | 2017-06-01 |
MX2016011557A (es) | 2017-04-13 |
US10100117B2 (en) | 2018-10-16 |
CN106536555A (zh) | 2017-03-22 |
JP6541236B2 (ja) | 2019-07-10 |
EP3114140A4 (en) | 2017-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016020643A2 (pt) | anticorpos específicos para receptor de fator de crescimento semelhante à insulina tipo 1 e uso dos mesmos | |
PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
CL2021000716A1 (es) | Constructos de anticuerpo para flt3 y cd3. (divisional sol. 201800269) | |
CL2021000519A1 (es) | (divisional de solicitud 732-2018) anticuerpo anti-vegf y su uso en el tratamiento de la angiogénesis patológica. | |
PE20190976A1 (es) | Anticuerpos de union a cd3 | |
PE20171654A1 (es) | Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer | |
PE20240096A1 (es) | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador | |
PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
PE20191551A1 (es) | Polipeptidos de union al receptor de transferrina disenados | |
AR101669A1 (es) | Constructos de anticuerpos para cdh19 y cd3 | |
CR20180065A (es) | Constructos de anticuerpo biespecíficos que se unen a egfrviii y cd3 | |
UA120048C2 (uk) | Антигензв'язуючий фрагмент антитіла, який специфічно зв'язується з рецептором інсуліноподібного фактора росту 1 (igf1r) | |
BR112014001573B8 (pt) | Molécula fv ao antígeno multivalente | |
BR112015022119A2 (pt) | Polipeptídeo, composto conjugado, composição farmacêutica, ácido nucleico, vetor, células hospedeiras procariótica e eucariótica, método de produção de um polipeptídeo, e, método de tratamento | |
EA201691780A1 (ru) | Наноструктурированный песок, способ получения наноструктурированного песка, способ разделения смеси загрязняющее вещество-вода с помощью наноструктурированного песка и дополнительные применения | |
AR110321A1 (es) | Anticuerpos antitau y métodos de uso | |
AR101400A1 (es) | Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido | |
PE20141522A1 (es) | Proteinas y peptidos modificados | |
CL2019000119A1 (es) | Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123. | |
AR117728A1 (es) | Moléculas superagonistas de unión al antígeno cd28 con diana tumoral | |
BR112019008351A2 (pt) | imunoglobulinas e usos das mesmas | |
PE20130207A1 (es) | Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones | |
PE20190415A1 (es) | Anticuerpos anti-basigin humanizados y uso de los mismos | |
CL2021002792A1 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
PE20191404A1 (es) | Proteinas de union al receptor de glucagon y metodos para usarlas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/12/2014, OBSERVADAS AS CONDICOES LEGAIS |